Advanced in Osteopenia

Dr. Linda Gaudiani

Endocrinology
Marin Healthcare Disrict
900 S Eliseo Dr Ste 201, 
Greenbrae, CA 
Advanced in Osteopenia
Marin Healthcare Disrict
900 S Eliseo Dr Ste 201, 
Greenbrae, CA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Linda Gaudiani is an Endocrinologist in Greenbrae, California. Dr. Gaudiani is rated as an Advanced provider by MediFind in the treatment of Osteopenia. Her top areas of expertise are Postmenopausal Osteoporosis, Osteoporosis, Maturity Onset Diabetes of the Young, and Melorheostosis.

Her clinical research consists of co-authoring 4 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Endocrinology
Licenses
Internal Medicine in CA
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D

Locations

Marin Healthcare Disrict
900 S Eliseo Dr Ste 201, Greenbrae, CA 94904

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

The Effect of Tirzepatide Versus Dulaglutide on Major Adverse Cardiovascular Events in Patients With Type 2 Diabetes (SURPASS-CVOT)
The Effect of Tirzepatide Versus Dulaglutide on Major Adverse Cardiovascular Events in Patients With Type 2 Diabetes (SURPASS-CVOT)
Enrollment Status: Completed
Publish Date: August 24, 2025
Intervention Type: Drug
Study Drugs: Tirzepatide, Dulaglutide
Study Phase: Phase 3
A Phase 3, Parallel-Design, Open-Label, Randomized Control Study to Evaluate the Efficacy and Safety of LY3209590 as a Weekly Basal Insulin Compared to Insulin Degludec in Insulin Naïve Adults With Type 2 Diabetes
A Phase 3, Parallel-Design, Open-Label, Randomized Control Study to Evaluate the Efficacy and Safety of LY3209590 as a Weekly Basal Insulin Compared to Insulin Degludec in Insulin Naïve Adults With Type 2 Diabetes
Enrollment Status: Completed
Publish Date: May 16, 2025
Intervention Type: Drug
Study Phase: Phase 3
A Phase 2 Study of Once-Daily LY3502970 Compared With Placebo in Participants Who Have Obesity or Are Overweight With Weight-Related Comorbidities
A Phase 2 Study of Once-Daily LY3502970 Compared With Placebo in Participants Who Have Obesity or Are Overweight With Weight-Related Comorbidities
Enrollment Status: Completed
Publish Date: September 13, 2023
Intervention Type: Drug
Study Drug: LY3502970
Study Phase: Phase 2
Efficacy and Safety of LY3298176 Once Weekly Versus Insulin Glargine in Patients With Type 2 Diabetes and Increased Cardiovascular Risk (SURPASS-4)
Efficacy and Safety of LY3298176 Once Weekly Versus Insulin Glargine in Patients With Type 2 Diabetes and Increased Cardiovascular Risk (SURPASS-4)
Enrollment Status: Completed
Publish Date: February 14, 2022
Intervention Type: Drug
Study Drugs: Tirzepatide, Insulin Glargine
Study Phase: Phase 3
A Phase 2, Randomized, Open-Label Trial to Evaluate the Safety and Efficacy of LY3209590 in Study Participants With Type 2 Diabetes Mellitus Previously Treated With Basal Insulin
A Phase 2, Randomized, Open-Label Trial to Evaluate the Safety and Efficacy of LY3209590 in Study Participants With Type 2 Diabetes Mellitus Previously Treated With Basal Insulin
Enrollment Status: Completed
Publish Date: March 08, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Prospective, Randomized, Double-Blind Comparison of LY900014 to Humalog in Adults With Type 1 Diabetes Using Continuous Subcutaneous Insulin Infusion
A Prospective, Randomized, Double-Blind Comparison of LY900014 to Humalog in Adults With Type 1 Diabetes Using Continuous Subcutaneous Insulin Infusion
Enrollment Status: Completed
Publish Date: January 22, 2021
Intervention Type: Drug
Study Phase: Phase 3
A Phase 2, Double-Blind, Placebo-Controlled, 18-Week Trial of Investigational Dulaglutide Doses Versus Placebo in Patients With Type 2 Diabetes on Metformin Monotherapy
A Phase 2, Double-Blind, Placebo-Controlled, 18-Week Trial of Investigational Dulaglutide Doses Versus Placebo in Patients With Type 2 Diabetes on Metformin Monotherapy
Enrollment Status: Completed
Publish Date: September 23, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 6 Less Clinical Trials

4 Total Publications

Unleashing the Potential of Blood Glucose Monitoring Data With the Ambulatory Glucose Profile Report.
Unleashing the Potential of Blood Glucose Monitoring Data With the Ambulatory Glucose Profile Report.
Journal: Clinical diabetes : a publication of the American Diabetes Association
Published: October 21, 2024
Similar Doctors
Distinguished in Osteopenia
Dr. Peter Sklarin
Endocrinology
Distinguished in Osteopenia
Dr. Peter Sklarin
Endocrinology

Radiology-Menlo Medical Clinic In Menlo Park-1300 Crane

1300 Crane St, 
Menlo Park, CA 
 (38.8 miles away)
650-498-6500
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Peter Sklarin is an Endocrinologist in Menlo Park, California. Dr. Sklarin is rated as a Distinguished provider by MediFind in the treatment of Osteopenia. His top areas of expertise are Thyroid Nodule, Osteoporosis, Postmenopausal Osteoporosis, and Osteopenia.

Distinguished in Osteopenia
Dr. Omar Murad
Endocrinology
Distinguished in Osteopenia
Dr. Omar Murad
Endocrinology

Berkeley Endocrine Clinic Inc.

3000 Colby St Ste 203B, 
Berkeley, CA 
 (17.0 miles away)
510-883-9005
Languages Spoken:
English
See accepted insurances

Omar Murad is an Endocrinologist in Berkeley, California. Dr. Murad is rated as a Distinguished provider by MediFind in the treatment of Osteopenia. His top areas of expertise are Osteoporosis, Postmenopausal Osteoporosis, Thyroid Nodule, and Melorheostosis with Osteopoikilosis.

Advanced in Osteopenia
Dr. Deborah Sellmeyer
Endocrinology
Advanced in Osteopenia
Dr. Deborah Sellmeyer
Endocrinology

Office

965 High St, 
Palo Alto, CA 
 (40.4 miles away)
650-723-4000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Deborah Sellmeyer is an Endocrinologist in Palo Alto, California. Dr. Sellmeyer is rated as a Distinguished provider by MediFind in the treatment of Osteopenia. Her top areas of expertise are Osteoporosis, Hypercalcemia, Milk-Alkali Syndrome, Postmenopausal Osteoporosis, and Gastric Bypass.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Gaudiani's expertise for a condition
ConditionClose
      View All 8 Advanced Conditions
      View All 23 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile